Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
Huawei EV partner Seres targets $1.7bn Hong Kong IPO amid record profit growth
Huawei EV partner Seres targets $1.7bn Hong Kong IPO amid record profit growth Seres Group, the main electric vehicle manufacturing partner of Huawei Technologies, is aiming to raise up to HK$13.2bn ($1.7bn) through a Hong Kong listing, highlighting renewed capital...
KKR, Apollo and Goldman invest $7bn to back Keurig Dr Pepper’s $18bn JDE Peet’s deal
KKR, Apollo and Goldman invest $7bn to back Keurig Dr Pepper’s $18bn JDE Peet’s deal Keurig Dr Pepper (KDP) has reached an agreement with private equity firms to provide funding for its beverage and coffee divisions, both of which will eventually become separate...
Goldman Sachs targets $10bn Kuwait mandate to boost private markets expansion in the Gulf
Goldman Sachs targets $10bn Kuwait mandate to boost private markets expansion in the Gulf Goldman Sachs is in discussions with the Kuwait Investment Authority (KIA) for a potential $10bn investment mandate, as the Wall Street firm intensifies its push into private...